Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 14, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
July 29, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
July 02, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
June 03, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
March 28, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 25, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
March 21, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
January 04, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
November 29, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
November 09, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
November 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
October 23, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 13, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
October 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
September 25, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
September 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
URGN
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
September 06, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
September 05, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
August 16, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
August 10, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
June 02, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
May 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
ELDN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.